CLEMASTINE FUMARATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Clemastine Fumarate, and when can generic versions of Clemastine Fumarate launch?
Clemastine Fumarate is a drug marketed by Actavis Mid Atlantic, Apotex Inc, Genus, New Heightsrx, Teva Pharms, Wockhardt Bio Ag, Ani Pharms, L Perrigo Co, Omnivium Pharms, Pld Acquisitions Llc, and Teva. and is included in eleven NDAs.
The generic ingredient in CLEMASTINE FUMARATE is clemastine fumarate. There are two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the clemastine fumarate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clemastine Fumarate
A generic version of CLEMASTINE FUMARATE was approved as clemastine fumarate by TEVA on January 31st, 1992.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CLEMASTINE FUMARATE?
- What are the global sales for CLEMASTINE FUMARATE?
- What is Average Wholesale Price for CLEMASTINE FUMARATE?
Summary for CLEMASTINE FUMARATE
US Patents: | 0 |
Applicants: | 11 |
NDAs: | 11 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 10 |
Patent Applications: | 3,376 |
DailyMed Link: | CLEMASTINE FUMARATE at DailyMed |
Recent Clinical Trials for CLEMASTINE FUMARATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
United States Department of Defense | Phase 1/Phase 2 |
University of California, San Francisco | Phase 1/Phase 2 |
Amsterdam UMC, location VUmc | Phase 3 |